Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management

被引:42
|
作者
Mustafa, S. Shahzad [1 ,2 ]
Ostrov, David [3 ]
Yerly, Daniel [4 ,5 ]
机构
[1] Rochester Reg Hlth Syst, Allergy & Clin Immunol, Rochester, NY 14611 USA
[2] Univ Rochester, Sch Med & Dent, Rochester, NY 14627 USA
[3] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL USA
[4] Univ Hosp, Dept Rheumatol Immunol & Allergol, Bern, Switzerland
[5] Univ Bern, Bern, Switzerland
关键词
Severe cutaneous adverse drug reaction(SCAR); Acute generalized exanthematous pustulosis(AGEP); Drug reaction with eosinophilia and systemic symptoms (DRESS); Stevens-Johnson syndrome (S[!text type='JS']JS[!/text]); Toxic epidermal necrolysis (TEN); HLA-associated drug hypersensitivity; TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON-SYNDROME; GENERALIZED EXANTHEMATOUS PUSTULOSIS; COLONY-STIMULATING FACTOR; AMNIOTIC MEMBRANE TRANSPLANTATION; INTRAVENOUS IMMUNOGLOBULIN; DRESS SYNDROME; HYPERSENSITIVITY SYNDROME; RETROSPECTIVE ANALYSIS; SYSTEMIC SYMPTOMS;
D O I
10.1007/s11882-018-0778-6
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Purpose of Study Immune-mediated adverse drug reactions occur commonly in clinical practice and include mild, self-limited cutaneous eruptions, IgE-mediated hypersensitivity, and severe cutaneous adverse drug reactions (SCAR). SCARs represent an uncommon but potentially life-threatening form of delayed T cell-mediated reaction. The spectrum of illness ranges from acute generalized exanthematous pustulosis (AGEP) to drug reaction with eosinophilia with systemic symptoms (DRESS), to the most severe form of illness, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Recent Findings There is emerging literature on the efficacy of cyclosporine in decreasing mortality in SJS/TEN. Summary The purpose of our review is to discuss the typical presentations of these conditions, with a special focus on identifying the culprit medication. We review risk factors for developing SCAR, including HLA alleles strongly associated with drug hypersensitivity. We conclude by discussing current strategies for the management of these conditions.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] NETosis Contributes to Severe Cutaneous Adverse Drug Reactions
    Brownell, I.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (04) : 992 - 992
  • [22] Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions
    Orime, Mari
    JOURNAL OF IMMUNOLOGY RESEARCH, 2017, 2017
  • [23] Pharmacogenetic markers of severe cutaneous adverse drug reactions
    Borroni, R. G.
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2014, 149 (02): : 219 - 226
  • [24] Incidence and risk factors for cutaneous adverse drug reactions in an intensive care unit
    Campos-Fernández, MDM
    Ponce-De-Leóon-Rosales, S
    Archer-Dubon, C
    Orozco-Topete, R
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2005, 57 (06): : 770 - 774
  • [25] Genetic Factors Associated With Severe Cutaneous Adverse Reactions
    Lozano, Roberto
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (20): : 2165 - 2166
  • [26] Management of severe cutaneous adverse drug reactions: what we still have to learn?
    Tanno, L. K.
    Tacco, M. C.
    Camporez, A.
    Fernandes, F.
    Pereira, V. A.
    Aun, W. T.
    Mello, J. F.
    ALLERGY, 2013, 68 : 143 - 143
  • [27] Spectrum of severe cutaneous adverse drug reactions among pediatric population and management options
    Abrol, Sameer
    Sharma, Rohini
    INDIAN JOURNAL OF PAEDIATRIC DERMATOLOGY, 2022, 23 (01) : 33 - 37
  • [28] The Risk of Tetrazepam to Induce Severe Cutaneous Adverse Reactions
    Mockenhaupt, Maja
    Sekula, Peggy
    Lebrun-Vignes, Benedicte
    Roujeau, Jean-Claude
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 318 - 319
  • [30] Recognition and management of severe cutaneous drug reactions
    Knowles, Sandra R.
    Shear, Neil H.
    DERMATOLOGIC CLINICS, 2007, 25 (02) : 245 - +